The Role of Cetuximab in the Treatment of Metastatic Colorectal Cancer

被引：0
作者：
Holubec, Lubos [1 ]
Liska, Vaclav [2 ]
Matejka, Vit M. [1 ]
Fiala, Ondrej [1 ]
Dreslerova, Jana [1 ]
Mrazkova, Petra [3 ,4 ]
Treska, Vladislav [2 ]
Finek, Jindrich [1 ]
机构：
[1] Charles Univ Prague, Dept Oncol & Radiotherapy, Sch Med, Prague, Czech Republic
[2] Charles Univ Prague, Dept Surg, Sch Med, Prague, Czech Republic
[3] Charles Univ Prague, Dept Radiol, Sch Med, Prague, Czech Republic
[4] Charles Univ Prague, Teaching Hosp Pilsen, Prague, Czech Republic
来源：
ANTICANCER RESEARCH | 2012年 / 32卷 / 09期
关键词：
KRAS; cetuximab; colorectal cancer; liver metastases; review; PLUS IRINOTECAN; 1ST-LINE TREATMENT; COMBINATION CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; LIVER METASTASES; OXALIPLATIN; FLUOROPYRIMIDINE; LEUCOVORIN; RESECTION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeted biological therapy is becoming a standard in personalized medicine for patients with advanced stages of cancer. Treatment with cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, represents an example of personalized anticancer the for patients with metastatic colorectal cancer and wild (non-mutated) type of the Kirsten rat sarcoma viral oncogene (KRAS). Here the role of cetuximab in treating metastatic colorectal cancer is discussed with a focus on the treatment of hepatic metastases.
引用
收藏
页码：4007 / 4011
页数：5
相关论文
共 30 条
[1]   Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J].
Adams, Richard A. ;
Meade, Angela M. ;
Seymour, Matthew T. ;
Wilson, Richard H. ;
Madi, Ayman ;
Fisher, David ;
Kenny, Sarah L. ;
Kay, Edward ;
Hodgkinson, Elizabeth ;
Pope, Malcolm ;
Rogers, Penny ;
Wasan, Harpreet ;
Falk, Stephen ;
Gollins, Simon ;
Hickish, Tamas ;
Bessell, Eric M. ;
Propper, David ;
Kennedy, M. John ;
Kaplan, Richard ;
Maughan, Timothy S. .
LANCET ONCOLOGY, 2011, 12 (07) :642-653
[2]   Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
de Braud, F. ;
Schuch, G. ;
Zubel, A. ;
Celik, I. ;
Schlichting, M. ;
Koralewski, P. .
ANNALS OF ONCOLOGY, 2011, 22 (07) :1535-1546
[3]   Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study [J].
Buzaid, Antonio C. ;
Mathias, Clarissa de Cerqueira ;
Perazzo, Florencia ;
Simon, Sergio D. ;
Fein, Luis ;
Hidalgo, Jorge ;
Murad, Andre M. ;
Esser, Regina ;
Senger, Stefanie ;
Lerzo, Guillermo .
CLINICAL COLORECTAL CANCER, 2010, 9 (05) :282-289
[4]   Targeted Therapeutic Agents for Colorectal Cancer [J].
Chee, Cheng E. ;
Sinicrope, Frank A. .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2010, 39 (03) :601-+
[5]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P3739
[6]   Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs [J].
Ciardiello, F ;
Tortora, G .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (10) :1348-1354
[7]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[8]   Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases [J].
Fernandez, FG ;
Ritter, J ;
Goodwin, JW ;
Linehan, DC ;
Hawkins, WG ;
Strasberg, SM .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2005, 200 (06) :845-853
[9]   Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial [J].
Folprecht, Gunnar ;
Gruenberger, Thomas ;
Bechstein, Wolf O. ;
Raab, Hans-Rudolf ;
Lordick, Florian ;
Hartmann, Joerg T. ;
Lang, Hauke ;
Frilling, Andrea ;
Stoehlmacher, Jan ;
Weitz, Juergen ;
Konopke, Ralf ;
Stroszczynski, Christian ;
Liersch, Torsten ;
Ockert, Detlev ;
Herrmann, Thomas ;
Goekkurt, Eray ;
Parisi, Fabio ;
Koehne, Claus-Henning .
LANCET ONCOLOGY, 2010, 11 (01) :38-47
[10]   Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial [J].
Garufi, C. ;
Torsello, A. ;
Tumolo, S. ;
Ettorre, G. M. ;
Zeuli, M. ;
Campanella, C. ;
Vennarecci, G. ;
Mottolese, M. ;
Sperduti, I. ;
Cognetti, F. .
BRITISH JOURNAL OF CANCER, 2010, 103 (10) :1542-1547
123